BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

Multiple Dose Study In Treatment Naive Subjects Infected With Hepatitis C Virus

Phase 1

Completed

Conditions: Chronic Hepatitis C

Interventions: Drug: BMS-824393

First Posted Date: 2009-09-03

Last Posted Date: 2011-01-25

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 37

Registration Number: NCT00971308

Locations: 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸
Elite Research Institute, Miami, Florida, United States
🇺🇸
Advanced Clinical Research Institute, Anaheim, California, United States

and more 3 locations

Single Dose Study of BMS-820836

Phase 1

Completed

Conditions: Depression

Interventions: Drug: BMS-820836
Drug: Placebo

First Posted Date: 2009-08-25

Last Posted Date: 2011-01-25

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 68

Registration Number: NCT00964912

Locations: 🇨🇦
Local Institution, Toronto, Ontario, Canada

Safety, Pharmacokinetics and Pharmacodynamics Study of BMS-866949 in Healthy Subjects

Phase 1

Completed

Conditions: Depression

Interventions: Drug: BMS-866949
Drug: Placebo

First Posted Date: 2009-07-30

Last Posted Date: 2011-01-25

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 64

Registration Number: NCT00949767

Locations: 🇸🇪
Local Institution, Uppsala, Sweden

Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM)

Phase 1

Terminated

Conditions: Glioblastoma

Interventions: Drug: Dasatinib
Drug: Lomustine

First Posted Date: 2009-07-29

Last Posted Date: 2012-08-31

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 28

Registration Number: NCT00948389

Locations: 🇨🇭
Local Institution, Lausanne, Switzerland

Japanese Bridging Study Conducted in the United States

Phase 1

Withdrawn

Conditions: Hepatitis C Virus

Interventions: Drug: BMS-791325
Drug: Placebo

First Posted Date: 2009-07-28

Last Posted Date: 2013-07-18

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT00947245

Locations: 🇺🇸
Local Institution, Cypress, California, United States

Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)

Phase 1

Completed

Conditions: Renal Cell Carcinoma
Non-hodgkin's Lymphoma

Interventions: Biological: MDX-1203

First Posted Date: 2009-07-23

Last Posted Date: 2013-05-22

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 46

Registration Number: NCT00944905

Locations: 🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States
🇺🇸
The University of Chicago, Chicago, Illinois, United States
🇺🇸
The University of Michigan Health System, Ann Arbor, Michigan, United States

and more 2 locations

Ex Vivo Human Thrombosis Chamber Study

Phase 1

Completed

Conditions: Cardiovascular Disease

Interventions: Drug: Clopidogrel
Drug: Aspirin

First Posted Date: 2009-07-09

Last Posted Date: 2011-02-23

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 15

Registration Number: NCT00935506

Locations: 🇺🇸
Mds Pharma Services, Neptune, New Jersey, United States

Abatacept Versus Adalimumab Head-to-Head

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Abatacept
Drug: Adalimumab

First Posted Date: 2009-06-30

Last Posted Date: 2014-02-04

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 869

Registration Number: NCT00929864

Locations: 🇺🇸
Laureate Clinical Research Group, Atlanta, Georgia, United States
🇺🇸
Mountain State Clinical Research, Clarksburg, West Virginia, United States
🇺🇸
Arthritis And Rheumatic Disease Specialties, Aventura, Florida, United States

and more 61 locations

A Study of BMS-833923 With Carboplatin and Etoposide Followed by BMS-833923 Alone in Subjects With Extensive-Stage Small Cell Lung Cancer

Phase 1

Completed

Conditions: Small Cell Lung Carcinoma

Interventions: Drug: BMS-833923
Drug: Carboplatin
Drug: Etoposide

First Posted Date: 2009-06-25

Last Posted Date: 2013-06-03

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 5

Registration Number: NCT00927875

Locations: 🇮🇪
Local Institution, Dublin, Ireland
🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States

Long-term Data Collection for Subjects in MDX-010 Studies

Completed

Conditions: Metastatic Melanoma

First Posted Date: 2009-06-25

Last Posted Date: 2010-04-26

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 160

Registration Number: NCT00928031

Locations: 🇺🇸
USC Norris Cancer Center, Los Angeles, California, United States
🇺🇸
Arizona Cancer Center, Tuscon, Arizona, United States
🇺🇸
Pacific Shores Medical Group, Long Beach, California, United States

and more 8 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy